Musumeci S, MacPhail A, Weisser Rohacek M, Erba A, Goldenberger D, Lang C, Colin-Benoit E, Leib S L, Sendi P, Chuard C, Erard V, Fournier C, Cobuccio L, Tagini F, Bertelli C, Senn L, Sommerstein R, Blättler G, Vieira Gomes C, Moraz M, Emonet S, Strahm C, Kohler P, Seiffert S N, Herzog K, Vuichard Gysin D, Brugger S D, Nolte O, Egli A, Weller D, Andrianaki A M, Zinkernagel A S, Vu D-L, Uribe Caparros A, Laurie G, Gaia N, Lazarevic V, François P, Schrenzel J
Department of Infectious Diseases, Department of Diagnostics, University Hospital Geneva, Geneva, Switzerland.
Faculty of Medicine, Geneva, Switzerland.
Eur J Clin Microbiol Infect Dis. 2025 Aug 5. doi: 10.1007/s10096-025-05229-y.
During the winter season of 2022-2023, numerous countries experienced a surge in invasive Streptococcus pyogenes (iGAS) infections. The role of viral coinfections in the post-COVID surge has not been elucidated. We report nation-wide data describing clinical presentation, microbiological characteristics, and associations with viral infection in adults during this period.
A multicenter retrospective cohort study was conducted across 10 hospitals in Switzerland, including adults (> 16 years old) with iGAS infection from November 2022 to February 2023. Descriptive analysis was performed. A multivariable logistic regression model was fitted to assess the impact of viral coinfection. In addition, genetic analysis was performed in available isolates.
A total of 194 patients were included, with a median age of 50 years (interquartile range [IQR]: 37-69). 17/194 (8.8%) were immunosuppressed and 40/194 (20.6%) exhibited concomitant viral infections, predominantly Influenza A (21/40, 53%). Illness severity was high: 65/194 (33.5%) of cases necessitated admission to an intensive care unit (ICU), and the 30-day mortality was 4% (n = 8). Among the available strains for genetic analysis (n = 48), heterogeneity was found although ST28-emm1 isolates (also known as M1UK) was predominant (22/48).
The post-COVID iGAS surge in Switzerland was associated with high levels of morbidity and mortality in immunocompetent adults. M1UK was predominant within the iGAS strains circulating in Switzerland during the study period and viral coinfection was a predictor for ICU admission and mortality.
在2022 - 2023年冬季,许多国家侵袭性化脓性链球菌(iGAS)感染激增。病毒合并感染在新冠疫情后感染激增中所起的作用尚未阐明。我们报告了这一时期全国范围内关于成人临床表现、微生物学特征以及与病毒感染相关性的数据。
在瑞士的10家医院开展了一项多中心回顾性队列研究,纳入2022年11月至2023年2月期间感染iGAS的成人(>16岁)。进行了描述性分析。采用多变量逻辑回归模型评估病毒合并感染的影响。此外,对可用分离株进行了基因分析。
共纳入194例患者,中位年龄为50岁(四分位间距[IQR]:37 - 69)。194例中有17例(8.8%)为免疫抑制患者,40例(20.6%)伴有病毒合并感染,主要为甲型流感(40例中的21例,53%)。疾病严重程度较高:194例中有65例(33.5%)需要入住重症监护病房(ICU),30天死亡率为4%(n = 8)。在用于基因分析的可用菌株(n = 48)中,发现存在异质性,尽管ST28 - emm1分离株(也称为M1UK)占主导(48例中的22例)。
瑞士新冠疫情后iGAS感染激增与免疫功能正常的成年人的高发病率和死亡率相关。在研究期间,M1UK在瑞士流行的iGAS菌株中占主导,病毒合并感染是入住ICU和死亡的一个预测因素。